Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Huuskonen, Mikko T ^a   Loppi, Sanna ^a   Dhungana, Hiramani ^a   Keksa Goldsteine, Velta ^a   Lemarchant, Sighild ^a   Korhonen, Paula ^a   Wojciechowski, Sara ^a   Pollari, Eveliina ^a   Valonen, Piia ^a   Koponen, Juho ^a   Takashima, Akihiko ^b   Landreth, Gary ^c   Goldsteins, Gundars ^a   Malm, Tarja ^a   Koistinaho, Jari ^a   Kanninen, Katja M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b GAKUSHUIN UNIVERSITY   (Japan)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; NEUROPROTECTIVE AGENT; TETRALIN DERIVATIVE;

AGING; ANIMAL; AUTOPHAGY; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; METABOLISM; MOUSE; PATHOLOGY; TAUOPATHY; THROMBOEMBOLISM; TRANSGENIC MOUSE;

AGING; ANIMALS; AUTOPHAGY; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; STROKE; TAUOPATHIES; TETRAHYDRONAPHTHALENES; THROMBOEMBOLISM;

EID: 84987750858     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33176     Document Type: Article

References (58)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117-171 (2015).
2. Chen, R. L., Balami, J. S., Esiri, M. M., Chen, L. K., Buchan, A. M. Ischemic stroke in the elderly: an overview of evidence. Nat. Rev. Neurol. 6, 256-265 (2010).
3. Fonarow, G. C. et al. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation 121, 879-891 (2010).
4. Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755-766 (2014).
5. Kovacs, G. G. et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 126, 365-384 (2013).
6. Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723-738 (2011).
7. Kaerst, L. et al. Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis. J. Neurol. 260, 2722-2727 (2013).
8. Zhou, J. et al. Association between stroke and Alzheimer's disease: systematic review and meta-analysis. J. Alzheimers Dis. 43, 479-489 (2015).
9. Holmes, B. B., Diamond, M. I. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J. Biol. Chem. 289, 19855-19861 (2014).
10. Chen, W., Sun, Y., Liu, K., Sun, X. Autophagy: a double-edged sword for neuronal survival after cerebral ischemia. Neural Regen. Res. 9, 1210-1216 (2014).
11. Wei, K., Wang, P., Miao, C. Y. A double-edged sword with therapeutic potential: an updated role of autophagy in ischemic cerebral injury. CNS Neurosci. Ther. 18, 879-886 (2012).
12. Henney, J. E. From the Food and Drug Administration. JAMA 283, 1131 (2000).
13. Abba, M. C. et al. Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models. BMC Med. Genomics 1, 40-8794-1-40 (2008).
14. McFarland, K. et al. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chem. Neurosci. 4, 1430-1438 (2013).
15. Riancho, J., Ruiz-Soto, M., Berciano, M. T., Berciano, J., Lafarga, M. Neuroprotective Effect of Bexarotene in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 9, 250 (2015).
16. Bomben, V. et al. Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol. Aging 35, 2091-2095 (2014).
17. Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506 (2012).
18. Fitz, N. F., Cronican, A. A., Lefterov, I., Koldamova, R. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340, 924-c (2013).
19. Mounier, A. et al. Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity. J. Neurosci. 35, 11862-11876 (2015).
20. Certo, M. et al. Activation of RXR/PPARgamma underlies neuroprotection by bexarotene in ischemic stroke. Pharmacol. Res. 102, 298-307 (2015).
21. Xu, L., Cao, F., Xu, F., He, B., Dong, Z. Bexarotene reduces blood-brain barrier permeability in cerebral ischemia-reperfusion injured rats. PLoS One 10, e0122744 (2015).
22. Orset, C. et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 38, 2771-2778 (2007).
23. Kimura, T. et al. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J. Biol. Chem. 285, 38692-38699 (2010).
24. Kilic, E., Hermann, D. M., Hossmann, K. A. A reproducible model of thromboembolic stroke in mice. Neuroreport 9, 2967-2970 (1998).
25. Landreth, G. E. et al. Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340, 924-g (2013).
26. Shuaib, A., Xu Wang, C., Yang, T., Noor, R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 33, 3033-3037 (2002).
27. Hetze, S., Romer, C., Teufelhart, C., Meisel, A., Engel, O. Gait analysis as a method for assessing neurological outcome in a mouse model of stroke. J. Neurosci. Methods 206, 7-14 (2012).
28. Denizot, F., Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89, 271-277 (1986).
29. Mizushima, N., Yoshimori, T. How to interpret LC3 immunoblotting. Autophagy 3, 542-545 (2007).
30. Palumbo, C. et al. c-Jun N-terminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition. J. Transl. Med. 14, 37-016-0796-x (2016).
31. Korhonen, P. et al. Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain Behav. Immun. 49, 322-336 (2015).
32. Wooley, C. M., Xing, S., Burgess, R. W., Cox, G. A., Seburn, K. L. Age, experience and genetic background influence treadmill walking in mice. Physiol. Behav. 96, 350-361 (2009).
33. Shoji, H., Takao, K., Hattori, S., Miyakawa, T. Age-related changes in behavior in C57BL/6J mice from young adulthood to middle age. Mol. Brain 9, 11-016-0191-9 (2016).
34. Corona, A. W., Kodoma, N., Casali, B. T., Landreth, G. E. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. J. Neuroimmune Pharmacol. 11, 61-72 (2016).
35. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1-222 (2016).
36. Ding, Y., Gao, H., Zhao, L., Wang, X., Zheng, M. Mitofusin 2-deficiency suppresses cell proliferation through disturbance of autophagy. PLoS One 10, e0121328 (2015).
37. Liao, G. et al. Reduced early hypoxic/ischemic brain damage is associated with increased GLT-1 levels in mice expressing mutant (P301L) human tau. Brain Res. 1247, 159-170 (2009).
38. Pineiro, R. et al. Relating MRI changes to motor deficit after ischemic stroke by segmentation of functional motor pathways. Stroke 31, 672-679 (2000).
39. Rosell, A. et al. Distal occlusion of the middle cerebral artery in mice: are we ready to assess long-term functional outcome? Transl. Stroke Res. 4, 297-307 (2013).
40. Seidler, R. D. et al. Motor control and aging: links to age-related brain structural, functional, and biochemical effects. Neurosci. Biobehav. Rev. 34, 721-733 (2010).
41. Tachibana, M. et al. Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Exp. Neurol. 277, 1-9 (2016).
42. Zhang, X. et al. Ginsenoside Rd attenuates tau protein phosphorylation via the PI3K/AKT/GSK-3beta pathway after transient forebrain ischemia. Neurochem. Res. 39, 1363-1373 (2014).
43. Song, B. et al. Phosphorylation of tau protein over time in rats subjected to transient brain ischemia. Neural Regen. Res. 8, 3173-3182 (2013).
44. Zheng, G. Q., Wang, X. M., Wang, Y., Wang, X. T. Tau as a potential novel therapeutic target in ischemic stroke. J. Cell. Biochem. 109, 26-29 (2010).
45. Merlini, M., Wanner, D., Nitsch, R. M. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's diseaserelated microvascular cerebral amyloid angiopathy. Acta Neuropathol (2016).
46. Ravikumar, B. et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 90, 1383-1435 (2010).
47. Nixon, R. A. The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983-997 (2013).
48. Koike, M. A., Green, K. N., Blurton-Jones, M., Laferla, F. M. Oligemic hypoperfusion differentially affects tau and amyloid-{beta}. Am. J. Pathol. 177, 300-310 (2010).
49. Frugier, T. et al. Evidence for the recruitment of autophagic vesicles in human brain after stroke. Neurochem. Int (2016).
50. Baek, S. H. et al. Modulation of mitochondrial function and autophagy mediates carnosine neuroprotection against ischemic brain damage. Stroke 45, 2438-2443 (2014).
51. Shibuya, Y. et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol. Aging 36, 2248-2259 (2015).
52. Cherra, S. J. 3rd, Dagda, R. K., Chu, C. T. Review: autophagy and neurodegeneration: survival at a cost? Neuropathol. Appl. Neurobiol. 36, 125-132 (2010).
53. Vosler, P. S., Graham, S. H., Wechsler, L. R., Chen, J. Mitochondrial targets for stroke: focusing basic science research toward development of clinically translatable therapeutics. Stroke 40, 3149-3155 (2009).
54. Volakakis, N. et al. Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate alpha-Synuclein Disrupted Gene Expression. J. Neurosci. 35, 14370-14385 (2015).
55. Rodriguez-Martin, T. et al. Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons. Neurobiol. Dis. 85, 1-10 (2016).
56. Delic, V. et al. Calorie restriction does not restore brain mitochondrial function in P301L tau mice, but it does decrease mitochondrial F0F1-ATPase activity. Mol. Cell. Neurosci. 67, 46-54 (2015).
57. David, D. C. et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 280, 23802-23814 (2005).
58. Zhu, J. et al. Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway. Am. J. Hypertens. 27, 1112-1124 (2014).